Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

Table 2

Summary diagnostic performance of miRNAs for prostate cancer.

Analysis	Group	Subgroup	Sensitivity (95% CI)	Specificity (95% CI)
Quantitative analysis	Overall		0.73 (0.62–0.82)	0.80 (0.70–0.87)
	Ethnicity	Asian	0.73 (0.63–0.81)	0.82 (0.63–0.80)
		Other ethnicities	0.74 (0.61–0.84)	0.83 (0.72–0.90)
	Sample types	Serum	0.81 (0.75–0.86)	0.78 (0.68–0.86)
		Plasma	0.78 (0.65–0.78)	0.80 (0.70–0.87)
	Source of control	Healthy control	0.79 (0.68–0.86)	0.82 (0.71–0.91)
		BPH/benign patients	0.75 (0.70–0.79)	0.77 (0.71–0.82)
Qualitative analysis	Overall
	Ethnicity	Asian	0.32 (0.28–0.36)	0.99 (0.96–0.99)
		Other ethnicities	0.24 (0.22–0.27)	0.98 (0.96–0.99)
	Sample types	Serum	0.19 (0.16–0.21)	0.99 (0.98–0.99)
		Plasma	0.43 (0.32–0.56)	0.95 (0.87–0.99)
	Source of control	Healthy control	0.21 (0.19–0.27)	0.99 (0.97–1.00)
		BPH/benign patients	0.27 (0.25–0.29)	0.97 (0.96–0.99)
	Assay methods	N-MSP	0.39 (0.33–0.45)	0.99 (0.97–1.00)
		Other methods	0.24 (0.22–0.26)	0.97 (0.96–0.98)
	Methylation gene location	GSTP1	0.41 (0.25–0.59)	0.98 (0.94–1.00)
		Other genes	0.22 (0.20–0.25)	0.98 (0.96–0.99)

MS-PCR (nonquantitative) and quantitative methylation-sensitive PCR; quantitative methylation-specific PCR; spectrophotometric assay; and bisulphite sequencing.